Study identification

PURI

https://redirect.ema.europa.eu/resource/21200

EU PAS number

EUPAS18060

Study ID

21200

Official title and acronym

A Survey of Medical Oncologist’s Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with Vectibix (20160258)

DARWIN EU® study

No

Study countries

United States

Study description

The study population consisted of practicing oncologists in the United States who treat patients with mCRC. Oncologists were recruited from a national database through a third party panel provider, M3 Global Research®. M3 Global Research® has access to over two million physicians and one million health care professionals globally for participation in both qualitative and quantitative studies. The oncologists were sampled at random and then stratified by size of institution, type of institution (academic cancer centers and community hospitals) and region within the United States to assess the following objectives: • Describe oncologist’s opinions regarding the management of dermatologic toxicities, including opinions regarding the timing of rash management in relation to the initiation of treatment with Vectibix and the manner in which the rash is managed. • Describe oncologist’s perceptions about the manner in which they preparing their patients for the possibility of developing dermatologic toxicities.

Study status

Finalised
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable